KLK3 and posterior cortical atrophy: Characterization of individual KLK activity, clinical utility of ABPP and related proteomic studies have strong potential to drive PCa biomarker discovery of active enzymes to supplement traditional prognostic strategies such as PSA marker screening as well as PROTAC design from a therapeutic standpoint.